Skip to main content
Equibles
ABBV logo

ABBV · AbbVie Inc. · Metrics

Track ABBV — free

Use ABBV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABBV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$255.00 +4.09 (+1.63%) At close · Sep 10
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$443.39B
Shares
1.77B

ABBV metrics

89 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$255.00
Market cap
$443.39B

Price action

20 metrics
Price change (1W)
-4.1%
Price change (30D)
+0.3%
Price change (3M)
+11.5%
Price change (6M)
+10.2%
Price change (YTD)
+9.8%
Price change (1Y)
+19.2%
Trailing year
Price change (5Y)
+133.9%
52-week high
$265.97
52-week low
$197.38
Change from 52-week high
-5.7%
Change from 52-week low
+27.1%
Annualized volatility
26.8%
Annualized volatility (3M)
29.1%
Beta
-0.1
RSI (14D)
44.5
Price vs SMA 50
-1.3%
Price vs SMA 200
+9.8%
Avg volume (3M)
6.39M
Relative volume
0.6
Average dollar volume
$1.59B

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
1.77B

Valuation

12 metrics
P / E (TTM)
70.9
Trailing earnings · reciprocal yield 1.4%
PEG ratio
0.2
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.9×
reciprocal yield 14.5%
P / book
—
FCF yield
4.1%
TTM · current market cap
Buyback yield
0.3%
P / FCF
24.3
reciprocal yield 4.1%
P / operating cash flow
22.7
reciprocal yield 4.4%
Earnings yield
1.4%

Historical valuation

8 metrics
P / E historical average (3Y)
76.5×
reciprocal yield 1.3%
P / E historical average (5Y)
58.2×
reciprocal yield 1.7%
EV / revenue historical average (3Y)
6.8×
reciprocal yield 14.7%
EV / revenue historical average (5Y)
6.4×
reciprocal yield 15.7%
EV / EBIT historical average (3Y)
31.4×
reciprocal yield 3.2%
EV / EBIT historical average (5Y)
26.7×
reciprocal yield 3.7%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
2.7%
Trailing 12 months
Payout ratio
189.8%
Shareholder yield
3.0%
Dividend / share (TTM)
$6.83
Dividend growth YoY
+5.6%
Dividend growth streak
5
Last ex-dividend
2026-07-15

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-31

Profitability

9 metrics
Gross margin
70.2%
Operating margin
26.2%
Trailing 12 months
Net margin
9.8%
Gross profit (TTM)
—
Operating profit (TTM)
$16.87B
Net income (TTM)
$6.31B
Trailing 12 months
Diluted EPS (TTM)
$3.54
FCF margin
28.3%
Effective tax rate
27.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.46

Growth

11 metrics
Revenue growth YoY
+10.2%
Year over year
Net income growth YoY
+285.2%
Revenue (TTM)
$64.39B
Trailing 12 months
EPS growth YoY
+290.4%
Shares change YoY
+0.0%
Year over year
Revenue CAGR (3Y)
+1.8%
Revenue CAGR (5Y)
+6.0%
EPS CAGR (3Y)
-29.1%
EPS CAGR (5Y)
-2.8%
FCF CAGR (3Y)
-9.8%
FCF CAGR (5Y)
+1.2%

Quality

14 metrics
Return on equity
—
Return on assets
4.7%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
—
Free cash flow (TTM)
$18.21B
Quick ratio
0.7
Interest coverage
5.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$6.57B
Total assets
$135.12B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$19.51B
Capital expenditures (TTM)
$1.30B
R&D (TTM)
$9.71B
SG&A (TTM)
$14.67B
Stock compensation (TTM)
$976.00M
R&D / revenue
15.1%
Stock compensation / revenue
1.5%

Ownership (13F)

3 metrics
13F filers
4,190
13F filer change QoQ
+68
Institutional ownership
76.6%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$8.18M
Insider-sentiment score
40 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1551152 CUSIP 00287Y109 13F (30d) 1057 filings 1001 filers Visit website Investor relations